MX337586B - Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. - Google Patents
Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.Info
- Publication number
- MX337586B MX337586B MX2012012901A MX2012012901A MX337586B MX 337586 B MX337586 B MX 337586B MX 2012012901 A MX2012012901 A MX 2012012901A MX 2012012901 A MX2012012901 A MX 2012012901A MX 337586 B MX337586 B MX 337586B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- related conditions
- uveitis
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere el uso de un anticuerpo anti-IL-1? o fragmento de unión del mismo, en la manufactura de un medicamento para inhibir uveítis en un sujeto en donde la uveítis es uveítis refractaria al tratamiento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33265810P | 2010-05-07 | 2010-05-07 | |
US33412510P | 2010-05-12 | 2010-05-12 | |
US201161444638P | 2011-02-18 | 2011-02-18 | |
PCT/US2011/035646 WO2011140522A1 (en) | 2010-05-07 | 2011-05-06 | METHODS FOR THE TREATMENT OF IL-1β RELATED CONDITIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012012901A MX2012012901A (es) | 2013-01-22 |
MX337586B true MX337586B (es) | 2016-03-11 |
Family
ID=44904117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012012901A MX337586B (es) | 2010-05-07 | 2011-05-06 | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. |
Country Status (14)
Country | Link |
---|---|
US (2) | US8551487B2 (es) |
EP (1) | EP2566520A4 (es) |
JP (1) | JP5904645B2 (es) |
KR (1) | KR20130065662A (es) |
CN (1) | CN102883748A (es) |
BR (1) | BR112012028557A2 (es) |
CA (1) | CA2797846A1 (es) |
EA (1) | EA201201526A1 (es) |
IL (1) | IL222890A0 (es) |
MX (1) | MX337586B (es) |
NZ (1) | NZ603191A (es) |
SG (2) | SG2014014724A (es) |
WO (1) | WO2011140522A1 (es) |
ZA (1) | ZA201208172B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
JP6401609B2 (ja) | 2011-04-29 | 2018-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 抗体反応を低下させる寛容原性合成ナノキャリア |
WO2014095808A1 (en) * | 2012-12-17 | 2014-06-26 | Delenex Therapeutics Ag | Antibodies against il-1 beta |
WO2014160468A1 (en) | 2013-03-13 | 2014-10-02 | Ryan Edwin | Dynamic optical coherence tomography device and method |
CN110841066A (zh) | 2013-05-03 | 2020-02-28 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
BR112017001311A2 (pt) | 2014-09-07 | 2017-11-14 | Selecta Biosciences Inc | métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon |
JP2017537896A (ja) * | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性抗体及び眼科に使用する方法 |
TW202339795A (zh) | 2015-11-03 | 2023-10-16 | 法商賽諾菲生物技術公司 | 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法 |
US10891729B2 (en) * | 2015-11-18 | 2021-01-12 | University Of Louisville Research Foundation, Inc. | Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology |
BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
WO2020047029A1 (en) | 2018-08-29 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
MX2021009242A (es) | 2019-01-31 | 2021-10-26 | Sanofi Biotechnology | Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica. |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0569687B1 (en) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
EP0161901B1 (en) | 1984-05-18 | 1993-12-01 | New England Medical Center Hospitals, Inc. | Human il-1 cDNA sequences encoding biologically-active human il-1 proteins |
US4762914A (en) | 1984-05-18 | 1988-08-09 | Auron Philip E | Truncated protein of interleukin-1 |
US5077219A (en) | 1984-05-18 | 1991-12-31 | New England Medical Center Hospitals | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US5474899A (en) | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
EP0364778B1 (en) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1beta |
CA2046303C (en) | 1989-02-27 | 2001-05-01 | Lee Gehrke | Il-1 biological activity inhibitors |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
AU2001259758A1 (en) | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
EP1423432A4 (en) | 2001-07-26 | 2006-01-11 | Lilly Co Eli | ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA) |
EP1578385A4 (en) | 2001-10-19 | 2011-11-09 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASES |
WO2003073982A2 (en) | 2002-02-28 | 2003-09-12 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
US7572770B2 (en) | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
ES2449578T3 (es) | 2002-09-06 | 2014-03-20 | Amgen Inc. | Anticuerpo monoclonal anti-IL-1R1 humano terapéutico |
AU2004207741B2 (en) | 2003-01-24 | 2011-02-10 | Applied Molecular Evolution, Inc | Human IL-1 beta antagonists |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
WO2005019259A2 (en) | 2003-08-25 | 2005-03-03 | Compugen Ltd. | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
JP4895811B2 (ja) * | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | サイトカイン阻害剤 |
US20050152850A1 (en) | 2004-01-09 | 2005-07-14 | Engebretson Steven P. | Methods and compositions for facilitating metabolic control |
US7732478B2 (en) | 2004-01-09 | 2010-06-08 | The Trustees Of Columbia University In The City Of New York | Methods for facilitating metabolic control |
WO2005084696A1 (en) | 2004-03-08 | 2005-09-15 | Universita'degli Studi Di Milano | Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr |
US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
US7121691B2 (en) * | 2004-09-22 | 2006-10-17 | Osram Sylvania Inc. | Lamp assembly with interchangeable light distributing cap |
WO2006081139A2 (en) | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
EP2322552B1 (en) * | 2005-06-21 | 2016-02-10 | Xoma (Us) Llc | IL-1beta binding antibodies and fragments thereof |
JP2009511545A (ja) | 2005-10-14 | 2009-03-19 | ノボ・ノルデイスク・エー/エス | Il−1インヒビターを使用する糖尿病の治療 |
WO2007120828A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
CN103405768A (zh) | 2006-12-20 | 2013-11-27 | 爱克索马技术有限公司 | 用于治疗IL-1β相关疾病的方法 |
EP2114443A4 (en) * | 2006-12-29 | 2011-08-10 | Abbott Lab | IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY |
CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
-
2011
- 2011-05-06 EA EA201201526A patent/EA201201526A1/ru unknown
- 2011-05-06 MX MX2012012901A patent/MX337586B/es active IP Right Grant
- 2011-05-06 WO PCT/US2011/035646 patent/WO2011140522A1/en active Application Filing
- 2011-05-06 EP EP20110778465 patent/EP2566520A4/en not_active Withdrawn
- 2011-05-06 SG SG2014014724A patent/SG2014014724A/en unknown
- 2011-05-06 KR KR20127031454A patent/KR20130065662A/ko not_active Application Discontinuation
- 2011-05-06 JP JP2013509314A patent/JP5904645B2/ja active Active
- 2011-05-06 CA CA 2797846 patent/CA2797846A1/en not_active Abandoned
- 2011-05-06 CN CN201180022684XA patent/CN102883748A/zh active Pending
- 2011-05-06 BR BR112012028557A patent/BR112012028557A2/pt not_active IP Right Cessation
- 2011-05-06 SG SG2012082301A patent/SG185473A1/en unknown
- 2011-05-06 US US13/102,768 patent/US8551487B2/en active Active
- 2011-05-06 NZ NZ603191A patent/NZ603191A/en not_active IP Right Cessation
-
2012
- 2012-10-30 ZA ZA2012/08172A patent/ZA201208172B/en unknown
- 2012-11-05 IL IL222890A patent/IL222890A0/en unknown
-
2013
- 2013-09-17 US US14/029,603 patent/US9139646B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20120014966A1 (en) | 2012-01-19 |
EA201201526A1 (ru) | 2013-06-28 |
NZ603191A (en) | 2015-02-27 |
ZA201208172B (en) | 2013-07-31 |
MX2012012901A (es) | 2013-01-22 |
US20140242090A1 (en) | 2014-08-28 |
JP5904645B2 (ja) | 2016-04-13 |
WO2011140522A1 (en) | 2011-11-10 |
US9139646B2 (en) | 2015-09-22 |
US8551487B2 (en) | 2013-10-08 |
CN102883748A (zh) | 2013-01-16 |
BR112012028557A2 (pt) | 2019-09-24 |
CA2797846A1 (en) | 2011-11-10 |
SG2014014724A (en) | 2014-07-30 |
EP2566520A4 (en) | 2014-02-12 |
JP2013526485A (ja) | 2013-06-24 |
EP2566520A1 (en) | 2013-03-13 |
IL222890A0 (en) | 2012-12-31 |
SG185473A1 (en) | 2012-12-28 |
KR20130065662A (ko) | 2013-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012012901A (es) | Metodos para tratamiento de condiciones relacionadas con interleucina-1beta. | |
AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MX2020011768A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2020011780A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2013008376A (es) | Composiciones y metodos para el tratamiento de cancer. | |
PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
EP2257647A4 (en) | MICRO-RNA-BASED PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF GAS CANCER | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
EP2569434A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | |
CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
IL221767B (en) | 3h – 7b binding molecules, their parts and their use | |
IL208027A0 (en) | Methods, compositions, and kits for treating pain and pruritus | |
WO2013056148A3 (en) | Scd1 antagonists for treating cancer | |
IL229022A0 (en) | Materials used to prepare preparations for the treatment, inhibition and/or prevention of a genetic disease in humans | |
MY148451A (en) | Antibodies against il-25 | |
MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
MX340683B (es) | Anticuerpos anti-vla-4. | |
MX2009009816A (es) | Anticuerpos monoclonales para el tratamiento del cancer. | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
WO2011100642A3 (en) | Method for treating hematological cancers | |
EP3524274A3 (en) | Managing the treatment of a cellular proliferative disorder using hom-1 expression | |
WO2013106460A3 (en) | Compositions and methods for treating malignant astrocytomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: XOMA (US) LLC |
|
FG | Grant or registration |